Latest News and Press Releases

Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.

Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.

Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.

Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.

Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)

Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.

Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.

Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004

Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS

PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...